Все категории
| Product Name | Описание | Action |
|---|---|---|
| Цетуксимаб | Trade Name : Erbitux Target : EGFR Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 650(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Aflibercept, Eylea, VEGF/PlGF, Zaltrap, VEGF-Trap, Анти-VEGF агент / ингибитор VEGF, VEGF ловушка / VEGF рецептор приманки, Антиангиогенный агент, Fusion Protein, CAS No. 862111-32-8 | Trade Name : Eylea Target : VEGF/PlGF Molecular Type : Fusion Protein Sales in 2025 (Millions of USD) : 7770(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Трастузумаб эмтанзин | Trade Name : Kadcyla Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 2000~2200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Трастузумаб дерукстекан | Trade Name : Enhertu Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 4500~5000(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Трастузумаб, Герцептин, Her2, терапия, ориентированная на HER2, моноклональные антитела против HER2, биологические антитела против онкологии / рака молочной железы, моноклональные антитела против опухолей, сверхэкспрессирующих HER2, CAS No 180288-69-1 | Trade Name : Herceptin Target : Her2 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 3000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ниволюмаб и берахайалуронидаза альфа- пмф,Opdivo SC,Opdivo подкожная инъекция,Opdivo Qvantig,BMS-986251,Подкожный ингибитор PD-1,Комбинационный продукт (901 и 932) | Trade Name : Opdivo Qvantig® Target : N/A Molecular Type : Combination Product (901 and 932) Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ниволумаб и релатлимаб-rmbw | Trade Name : Opdualag Target : PD-1, LAG-3 Molecular Type : Fixed-dose Combination (902 and 962) Sales in 2025 (Millions of USD) : 1000~1200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get ... |
|
| Ниволумаб | Trade Name : Opdivo Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 12000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
